Vaccine hesitancy is not simply ignorance that more information will fix. Research consistently shows that providing parents with vaccine safety data is not, on its own, what moves people from uncertain to confident. The decision to vaccinate a child is shaped by trust – in institutions, in the health professionals encountered personally, and in the information landscape that surrounds the family. Understanding why parents have concerns is a more useful starting point than refuting a list of myths.
This article addresses the most common concerns about childhood vaccination in the UK, with honest information about what is known, what is genuinely uncertain, and what is well-established. The aim is not to dismiss concern but to provide a reliable basis for a real decision.
Healthbooq (healthbooq.com/apps/healthbooq-kids) covers immunisation and child health in the UK.
Why Vaccine Hesitancy Exists
Vaccine hesitancy is not a single phenomenon. Heidi Larson at the London School of Hygiene and Tropical Medicine, whose Vaccine Confidence Project monitors vaccine trust globally, identifies several distinct drivers. Complacency – the sense that vaccine-preventable diseases are no longer a real threat – is one: when parents haven't seen whooping cough, measles, or Hib meningitis, the disease feels more abstract than the injection. Convenience – difficulty accessing services, confusing scheduling – contributes. And confidence – trust in the safety and effectiveness of vaccines and in the systems that recommend and deliver them – is the factor most affected by misinformation.
The internet has allowed vaccine-hesitant content to reach parents at the moment when they're most searching: around the first set of vaccinations at two months of age, when they are processing the vulnerability of a new baby and encountering medical information for the first time. The Wakefield MMR-autism claim, a fraudulent study published in The Lancet in 1998 and retracted in 2010, is still the most cited vaccine-related concern in parenting communities despite more than twenty years of thorough refutation by numerous independent research groups. Brian Taylor and colleagues at the Royal Free Hospital provided some of the earliest refutations; subsequent large-scale studies involving millions of children in Denmark (Madsen et al., NEJM 2002), Japan, and across multiple countries have consistently shown no association between MMR and autism.
The MMR and Autism Question
The original Wakefield study involved twelve children, was funded by lawyers acting for parents seeking legal action against vaccine manufacturers, and involved undisclosed conflicts of interest and falsified data. Richard Horton, the editor of The Lancet, described the retraction in 2010 as a response to "clear evidence of falsification." The General Medical Council struck Wakefield off the medical register for serious professional misconduct.
The science since is extensive. A 2019 Cochrane review of MMR vaccination by Pauline Papadopoulos and colleagues, covering over 1.2 million children across multiple high-quality studies, found no credible link between MMR and autism, Crohn's disease, or any serious adverse events. The rise in autism diagnoses in recent decades reflects changes in diagnostic criteria and increased recognition, not vaccination rates. Autism traits are present from birth – detectable in home videos of children later diagnosed, made before vaccination age.
The genuine autism story is not about MMR: it is about genetics, early prenatal development, and environmental factors that are the subject of active and legitimate research, in which vaccines play no part.
What the Real Side Effects of Vaccines Are
All vaccines have side effects. Being clear about this – rather than appearing to minimise or deny it – is part of building justified confidence.
Common mild side effects that are expected and normal: soreness, redness, and swelling at the injection site; low-grade fever in the 24-48 hours after vaccination; irritability; drowsiness or disturbed sleep. For the MMR, a fever and a mild measles-like rash 7-11 days after vaccination occurs in around 5-10% of children – this is the immune response to the live attenuated measles virus, not infection.
Febrile seizures occur in around 1 in 3,000 children after the MMR – a frightening event but one that does not cause brain damage and has no long-term consequences. This risk is considerably lower than the risk of febrile seizures from wild measles infection itself.
Serious adverse events after vaccination are rare. Anaphylaxis after vaccination occurs at a rate of around 1-2 per million doses, which is why vaccination is given in settings where anaphylaxis can be managed and children are observed for 15-20 minutes afterwards. The Yellow Card system in the UK allows healthcare professionals and members of the public to report adverse events following vaccination, and these reports are monitored by the MHRA (Medicines and Healthcare products Regulatory Agency).
The dose-benefit calculation for standard childhood vaccines is strongly in favour of vaccination. Measles has a case fatality rate of around 1-2 per thousand in high-income countries – higher in malnourished children or those with immune deficiencies. Measles encephalitis occurs in around 1 in 1,000 cases. The risk of serious harm from the MMR is orders of magnitude lower than the risk from the disease.
The Herd Immunity Question
Herd immunity – also called population immunity – is the protection of the unvaccinated minority that occurs when a sufficiently high proportion of the population is immune to a disease. For measles, this threshold is around 95%: if 95% of the population is immune (through vaccination or prior infection), the virus can no longer spread effectively and even those who can't be vaccinated (newborns, immunocompromised individuals) are protected.
When vaccination rates fall below this threshold, outbreaks occur. The 2019 measles outbreaks in England, the US, and across Europe followed declines in MMR coverage attributable partly to the Wakefield affair's long tail. Children under one year (too young to be vaccinated), children with leukaemia, and children who are immunosuppressed for other reasons rely entirely on those around them being vaccinated.
This is the collective dimension of vaccination: the decision is not only about an individual child's risk-benefit balance but also about what population of immunity surrounds the most vulnerable children.
Practical Points for Concerned Parents
For parents with genuine concerns about vaccination, the most helpful conversation is with a health visitor or GP who is willing to discuss specific worries without dismissal. A clinician who responds to concerns with "there's nothing to worry about, these vaccines are completely safe" may technically be correct but is not being useful: that framing closes rather than opens the conversation.
Delaying vaccination to allow more time to consider is not without risk: the first months of a baby's life are the period of highest vulnerability to the diseases the early vaccines protect against. The vaccination schedule is designed around when the immune system is most at risk, not around parental convenience. For Hib meningitis and whooping cough, the highest-risk period for severe disease is the first few months.
Parents who want to understand the evidence base for individual vaccines can consult the NHS's detailed immunisation information, the Green Book (Public Health England's immunisation guidance, available online), and the Cochrane Reviews of individual vaccines, which are the highest standard of evidence synthesis available.
Key Takeaways
Vaccine hesitancy – from outright refusal to uncertainty and delayed uptake – has become one of the most significant public health challenges of the past decade. The WHO listed vaccine hesitancy among the ten threats to global health in 2019. The roots are complex: distrust of institutions, misinformation, a normalisation of rare vaccine-preventable diseases, and specific concerns that are sometimes poorly addressed by health professionals. The MMR-autism claim, made in a 1998 paper by Andrew Wakefield, was fraudulent and has been thoroughly refuted. Effective communication around vaccination requires acknowledging genuine concerns, providing accurate risk-benefit information, and building trust rather than dismissing worry.
